INTRODUCTION {#s1}
============

According to the data provided by *Cancer statistics, 2017*, around 1,688,780 new cancer patients and 600,920 cancer-related deaths will develop in America in 2017 \[[@R1]\]. And, it was estimated that a number of 4,292,000 new cancer patients and 2,814,000 cancer-related deaths would occur in China in 2015 \[[@R2]\]. These data declared that cancer has represented a substantial public health burden. It has been proved that cancer was a multifactorial disease due to dynamic interactions between the environmental exposures and host genetic background. The mechanisms of inherited factors effecting on tumor is still not known clearly, though the carcinogenesis and tumor-immunity function of cytokines have been well established \[[@R3]\]. In fact, one of the pivotal control mechanisms in pathogenesis of tumor was considered to be cytokine-mediated immunity \[[@R4]\]. For instance, interferon, a cytokine with strongly anti-tumor effects, was widely used in treatment of many cancers, especially for hematological malignant tumor such as chronic myeloid leukemia and hairy cell leukemia \[[@R5]\]. Likewise, Interleukins (ILs) were promising in immunotherapy for many cancers because they can enhance the immune response against both infections and tumors. In previous clinical trials several candidates of ILs (such as IL-1a, IL-2, and IL-18) were failed to show corresponding effectiveness on tumors, and other ILs (including IL-7, IL-10, IL-15 and IL-21) showed severe adverse side effects during treatment \[[@R6]\]. Thus, exploration and discovery new, effective immune-modulators are imperative. Interleukin-12 (IL-12), which is characteristic as a link between the innate and acquired immune response \[[@R7]\], is one of the most potential candidates for tumor immunotherapy.

IL-12 is mainly produced by activated antigen-presenting cells, such as macrophages, dendritic cells, and monocytes. As a heterodimeric cytokine, IL-12 protein is formed by two disulfide-linked polypeptide chains comprising p35 and p40, which are encoded by IL-12A gene and IL-12B gene, independently. And it mapped to human chromosomes 3p12-q13.2 and 5q31-33 \[[@R8]\]. IL-12 can potently induce the differentiation of naive CD4+ T cell to Th1 cells and augment cytotoxic T lymphocyte responses, as well as promote activation of natural killer (NK) cells, and secretion of interferon-γ \[[@R9]\]. Moreover, IL-12 can impair the mechanism of neoangiogenesis in tumors by antagonizing the pro-angiogenic signals. Animal experiments extensively showed that both nonspecific and specific antitumor immune responses were enhanced after transfecting IL-12 gene into tumor cells \[[@R10], [@R11]\]. In addition, clinical trials indicated that serum level of IL-12 was related to the severity of gastric cancer patients \[[@R12]\], and also influenced the progression of colorectal cancer \[[@R13]\].

Because of these pleiotropic activities of IL-12, dozens of molecular epidemiologic studies have explored the influences of IL-12 polymorphisms on susceptibility of various cancers, including hepatocellular carcinoma \[[@R14]--[@R19]\], colorectal cancer \[[@R13], [@R20], [@R21]\] and gastric cancer \[[@R22]--[@R24]\], etc. The most commonly fascinating loci were rs3212227 in IL-12B gene, rs568408 and rs2243115 in IL-12A genes, perhaps owing to their function to influence IL-12 gene expression, reduce protein synthesis, and subsequently result in cancer. Unfortunately, the functional role on cancer risk that IL-12 gene polymorphisms played was still uncertain. For instance, a study performed by Sun et al. found that IL-12A rs568408 may increase the susceptibility on colorectal cancer \[[@R20]\], being contrary to the conclusion of the study by Huang et al. which suggested IL-12A rs568408 was not associated with colorectal cancer\[[@R21]\]. And, a previous study reported that the loci of rs3212227 in IL-12B gene definitely contributed to increasing cervical cancer risk in Chinese population \[[@R25]\]. However, another study found IL-12B rs3212227 polymorphism exhibited a protective effect \[[@R26]\], while an earlier study showed that there was no relationship between cervical cancer and IL-12B rs3212227 in Korean population \[[@R27]\]. Hence, we conducted this study according to currently published data to investigate the precise relationship between these three common variants and various cancers risk.

RESULTS {#s2}
=======

Characteristics of eligible studies {#s2_1}
-----------------------------------

As the flow diagram showed Figure [1](#F1){ref-type="fig"}, we identified a total of 72 publications from the PubMed, web of knowledge, Embase, WanFang, VIP and CNKI databases using the search words, fifteen obviously irrelevant studies and six reviews were excluded firstly. Fourteen studies were excluded from our meta-analysis after screening the titles and abstracts because they were not researching on rs568408, rs2243115 and rs3212227 polymorphisms (2 studies) or cancer (4 studies), and 8 studies were excluded for not case-control studies. The remaining 37 studies evaluated for eligibility by reading the full-text; 3 studies were excluded owing to either lack of complete data or presence of irrelevant data that focused on other IL-12 polymorphisms; one study was written neither in English nor in Chinese. Ultimately, 33 studies with 10,587 cancer cases and 12,040 cancer-free controls were elected in this meta-analysis to explored the relationship of IL-12A rs568408 (10 studies), IL-12A rs2243115 (9 studies), and IL-12B rs3212227 (30 studies) polymorphisms and cancer risk. According to the Newcastle-Ottawa Scale (NOS), all included studies obtained a score of 6 or more, which was defined as a high quality. Among these, 3 studies were written in Chinese and 30 studies in English. The genotype frequencies in 2 studies \[[@R17], [@R18]\] were not provided completely, we could only evaluated the data based on dominant model. The eligible studies involved several different cancer types including hepatocellular, colorectal, gastric, cervical, breast, prostate, osteosarcoma, esophageal, brain, cervical, ovarian, nasopharyngeal, lung, Non-Hodgkin lymphoma, and cutaneous malignant melanoma. Every study was in according with HWE except for two \[[@R20], [@R28]\]. The main characteristics of the included studies are presented in Table [1](#T1){ref-type="table"}. The distributions of rs568408, rs2243115, and rs3212227 polymorphisms of IL-12 among cases and controls are shown in Table [2](#T2){ref-type="table"}.

![The flow diagram of the meta-analysis, according to the PRISMA 2009\
CNKI: China National Knowledge Infrastructure.](oncotarget-08-29795-g001){#F1}

###### Characteristics of the studies included in the meta-analysis

  Study                     Year   Country    Ethnic      Method      Source of control   Cancer type   Case/control   SNP.    NOS
  ------------------------- ------ ---------- ----------- ----------- ------------------- ------------- -------------- ------- -----
  Tan\[[@R14]\]             2015   China      Asian       iMLDR       Population          HCC           395/686        1,2,3   7
  Sun\[[@R20]\]             2015   China      Asian       PCR-RFLP    Hospital            CRC           257/236        1,2,3   7
  Yin\[[@R22]\]             2015   China      Asian       SNPscan     Hospital            GAC           234/476        2,3     7
  Jafarzadeh\[[@R35]\]      2015   Iran       Asian       PCR-RFLP    Population          BC            100/100        3       6
  Winchester\[[@R36]\]      2015   USA        Caucasian   MassArray   Population          PC            566/530        3       9
  Saxena\[[@R15]\]          2014   India      Asian       PCR-RFLP    Population          HCC           59/153         3       6
  wang\[[@R37]\]            2013   China      Asian       PCR-RFLP    Population          OSC           106/210        1,2,3   7
  Sun\[[@R38]\]             2013   China      Asian       SNPscan     Hospital            EC            380/380        3       8
  Jaiswal\[[@R39]\]         2013   Indian     Asian       PCR-RFLP    Hospital            BLC           200/200        3       6
  Tao\[[@R40]\]             2012   Mixed      Asian       PCR-RFLP    Population          EC            426/432        1,3     6
  Sima\[[@R41]\]            2012   China      Asian       PCR-RFLP    Hospital            BT            170/222        2,3     7
  Kaarvatn\[[@R42]\]        2012   Croatia    Caucasian   TaqMan      Mixed               BC            191/194        3       6
  Carvalho\[[@R26]\]        2012   Brazil     Mixed       PCR-RFLP    Population          CC            162/76         3       6
  Roszak\[[@R25]\]          2012   Poland     Caucasian   PCR-RFLP    Population          CC            405/405        1,3     7
  Hu\[[@R43]\]              2012   China      Asian       PCR-RFLP    Hospital            OC            92/38          3       6
  Huang\[[@R21]\]           2012   China      Asian       PCR-RFLP    Hospital            CRC           410/450        3       6
  Liu\[[@R16]\]             2011   China      Asian       PCR-RFLP    population          HCC           869/891        1,2,3   9
  Chaaben\[[@R44]\]         2011   Tunisia    African     Taqman      population          NPC           247/284        3       6
  Ter-Minassian\[[@R45]\]   2011   USA        Caucasian   MassArray   Population          BT            261/319        2       8
  Yang\[[@R19]\]            2011   China      Asian       Taqman      Hospital            HCC           608/612        3       6
  Wu\[[@R24]\]              2009   China      Asian       PCR-RFLP    Population          GC            1035/1073      3       7
  Chen\[[@R46]\]            2009   China      Asian       PCR-RFLP    population          CC            404/404        1,2,3   9
  Miteva\[[@R13]\]          2009   Bulgaria   Caucasian   PCR--RFLP   Hospital            CRC           85/134         3       6
  Wei\[[@R47]\]             2009   China      Asian       PCR--RFLP   Hospital            NPC           302/310        3       6
  Zhao\[[@R48]\]            2009   China      Asian       PCR--RFLP   Hospital            BT            210/220        3       6
  Ognjanovic\[[@R17]\]      2009   USA        Caucasian   Taqman      population          HCC           117/223        3       9
  Han\[[@R27]\]             2008   Korea      Asian       PCR--RFLP   Hospital            CC            150/179        3       7
  Hou\[[@R23]\]             2007   USA        Caucasian   TaqMan      Population          GC            257/428        1       6
  Lee\[[@R49]\]             2007   USA        Asian       TaqMan      Population          LC            119/113        1       8
  Wang\[[@R50]\]            2006   USA        Caucasian   TaqMan      Population          NHL           1130/941       1,3     9
  Nieters\[[@R18]\]         2005   China      Asian       PCR--RFLP   Hospital            HCC           250/250        3       8
  Howell\[[@R51]\]          2003   UK         Caucasian   ARMS-PCR    Hospital            CMM           145/229        3       7

PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; HCC: hepatocellular carcinoma; GC: gastric cancer; CRC: colorectal cancer; BC: breast cancer; PC: prostate cancer; OSC: osteosarcoma; EC: esophageal cancer; BLC: bladder cancer; BT: brain tumor; CC: cervical cancer; OC: ovarian carcinoma; NPC: nasopharyngeal cancer; GC: gastric cancer; LC: lung cancer; NHL: non-Hodgkin lymphoma; CMM: cutaneous malignant melanoma. SNP No.1: rs568408 (3′ UTR G\>A) in IL-12A; 2: rs2243115 (5′UTR T\>G) in IL-12A; 3: rs3212227 (3′ UTR A\>C) in IL-12B; NOS: the Newcastle-Ottawa Scale.

###### Genotype distribution and allele frequency of IL-12 polymorphisms

  First author                   Genotype (N)   Allele frequency (N)   MAF   HWE                                                              
  ------------------------------ -------------- ---------------------- ----- ----- ------ ----- ----- ----- ------ ----- ------ ----- ------- -------
  **rs568408**                                                                                                                                
  Tan 2015\[[@R14]\]             395            313                    76    6     686    511   161   14    702    80    1183   189   0.102   0.750
  Sun 2015\[[@R20]\]             257            172                    83    2     236    181   55    0     427    89    417    55    0.172   0.040
  Wang2013\[[@R37]\]             106            66                     37    3     210    156   47    7     169    61    359    61    0.265   0.150
  Tao 2012\[[@R40]\]             430            276                    142   12    432    304   112   16    694    184   720    144   0.210   0.170
  Roszak 2012\[[@R25]\]          405            253                    128   24    450    306   125   19    634    140   737    163   0.181   0.180
  Liu 2011\[[@R16]\]             802            504                    277   21    861    631   220   10    1285   289   1482   240   0.184   0.060
  Chen 2009\[[@R46]\]            404            253                    145   6     404    285   112   7     651    221   682    126   0.253   0.290
  Hou 2007\[[@R23]\]             257            211                    8     38    428    306   112   10    430    8     724    132   0.018   0.950
  Lee 2007\[[@R49]\]             118            101                    17    0     113    81    31    1     219    81    193    33    0.270   0.290
  Wang 2006\[[@R50]\]            941            671                    238   32    1130   839   270   21    1580   238   1948   312   0.131   0.890
  **rs2243115**                                                                                                                               
  Tan 2015\[[@R14]\]             395            326                    63    6     685    549   128   8     715    75    1226   144   0.095   0.861
  Sun 2015\[[@R20]\]             257            225                    31    1     236    212   24    0     481    33    448    24    0.064   0.411
  Yin 2015\[[@R22]\]             235            197                    36    2     466    387   75    4     430    40    849    83    0.085   0.862
  Wang2013\[[@R37]\]             106            89                     16    1     210    175   31    4     194    18    381    39    0.085   0.073
  Sun 2013\[[@R38]\]             368            311                    56    1     370    308   58    4     678    58    674    66    0.079   0.499
  Sima 2012\[[@R41]\]            170            140                    25    5     222    198   24    0     305    35    420    24    0.103   0.395
  Liu 2011\[[@R16]\]             861            735                    125   1     874    732   137   5     1595   127   1601   147   0.074   0.604
  Ter-Minassian 2011\[[@R45]\]   248            115                    113   20    317    180   114   23    343    153   474    160   0.308   0.403
  Chen 2009\[[@R46]\]            404            342                    60    2     404    337   64    3     744    64    738    70    0.079   0.984
  **rs3212227**                                                                                                                               
  Tan 2015\[[@R14]\]             395            104                    201   90    686    200   347   139   409    381   747    625   0.482   0.605
  Sun 2015\[[@R20]\]             257            69                     140   48    236    71    124   41    278    236   266    206   0.459   0.295
  Yin 2015\[[@R22]\]             234            60                     132   42    466    152   221   93    252    216   525    407   0.462   0.436
  Jafarzadeh 2015\[[@R35]\]      100            58                     32    10    100    59    33    8     148    52    151    49    0.260   0.280
  Winchester 2015\[[@R36]\]      866            535                    274   57    830    568   227   35    1344   388   1363   297   0.224   0.046
  Saxena 2014\[[@R15]\]          59             19                     31    9     148    63    71    14    69     49    197    99    0.415   0.345
  Wang 2013\[[@R37]\]            106            27                     50    29    210    78    101   31    104    108   257    163   0.509   0.585
  Sun 2013\[[@R38]\]             368            116                    176   76    370    112   179   79    408    328   403    337   0.446   0.635
  Jaiswal 2013\[[@R39]\]         200            87                     94    19    200    111   74    15    268    132   296    104   0.330   0.590
  Tao 2012\[[@R40]\]             426            109                    216   101   432    148   213   71    434    418   509    355   0.491   0.701
  Sima 2012\[[@R41]\]            170            66                     86    18    222    71    116   35    218    122   258    186   0.359   0.275
  Kaarvatn 2012\[[@R42]\]        191            126                    59    6     194    104   73    17    311    71    281    107   0.186   0.419
  Carvalho 2012\[[@R26]\]        162            100                    49    13    76     31    37    8     249    75    99     53    0.231   0.531
  Roszak 2012\[[@R25]\]          405            212                    174   19    450    289   151   10    598    212   729    171   0.262   0.056
  Hu 2012\[[@R43]\]              92             16                     42    34    38     13    16    9     74     110   42     34    0.598   0.360
  Huang 2012\[[@R21]\]           410            93                     219   98    450    124   230   96    405    415   478    422   0.506   0.578
  Liu 2011\[[@R16]\]             831            249                    422   160   844    272   414   158   920    742   958    730   0.446   0.983
  Chaaben 2011\[[@R44]\]         247            74                     124   49    284    135   118   31    272    222   388    180   0.449   0.497
  Yang2011\[[@R19]\]             608            156                    309   143   612    195   302   115   621    595   692    532   0.489   0.919
  Wu 2009\[[@R24]\]              1035           347                    508   180   1073   333   554   186   1202   868   1220   926   0.419   0.086
  Chen 2009\[[@R46]\]            404            127                    199   78    404    150   185   69    453    355   485    323   0.439   0.357
  Miteva 2009\[[@R13]\]          85             50                     31    4     134    80    45    9     131    39    205    63    0.229   0.443
  Wei 2009\[[@R47]\]             302            58                     165   79    310    98    152   60    281    323   348    272   0.535   0.938
  Zhao 2009\[[@R48]\]            210            38                     115   57    220    70    106   44    191    229   246    194   0.545   0.736
  Ognjanovic 2009\[[@R17]\]      117            57                     /     /     223    128   /     /     /      /     /      /     /       /
  Tamandani 2009\[[@R28]\]       200            63                     134   3     200    88    104   8     260    140   280    120   0.350   0.001
  Han 2008\[[@R27]\]             150            32                     87    31    179    52    88    39    151    149   192    166   0.497   0.877
  Wang 2006\[[@R50]\]            926            565                    310   51    1110   641   397   72    1440   412   1679   541   0.222   0.322
  Nieters 2005\[[@R18]\]         249            56                     /     /     250    72    /     /     /      /     /      /     /       /
  Howell2003\[[@R51]\]           145            95                     42    8     229    139   77    13    232    58    355    103   0.200   0.591

A: the major allele, B: the minor allele, MAF: minor allele frequencies; HWE: Hardy--Weinberg equilibrium.

Quantitative synthesis of rs568408 and rs2243115 polymorphisms {#s2_2}
--------------------------------------------------------------

In the meta-analysis, we derived data from 10 studies including 4115 cancer cases and 4950 cancer-free controls for rs568408, 9 studies containing 3004 cancer cases and 3784 cancer-free controls for rs2243115, respectively.

The pooled analysis proved that IL-12A rs568408 polymorphisms was associated with overall cancer risk on allele comparison (A vs. G: OR = 1.18, 95%CI: 1.01-1.38, *P* = 0.04). However, no significant association was found after excluding one study \[[@R20]\] not according to the HWE (All *P* \> 0.05, Figure [2](#F2){ref-type="fig"}). In stratified analysis by ethnicity, we observed an increased risk of overall cancers among Caucasians (recessive model: OR = 2.63, 95% CI = 1.05-6.56; homozygote model: OR = 2.46, 5% CI = 1.20-5.06; allele model: OR = 1.19, 95% CI = 1.05-1.35). The subgroup analysis by cancer type showed rs568408 polymorphism increased cervical cancer risk under three genetic models (allele model: OR = 1.28, 95% CI = 1.07-1.52; heterozygous model: OR = 1.34, 95% CI = 1.09-1.66; dominate model: OR = 1.35, 95% CI = 1.10-1.65). Rs2243115 polymorphism was associated with brain tumor under dominate model (OR = 1.58, 95% CI = 1.18-2.11), heterozygous model (OR = 1.53, 95 % CI = 1.13-2.07) and allele model (OR = 1.52, 95% CI = 1.03-2.24). However, the subgroup analysis based on source of controls proved IL-12A polymorphisms (rs568408 and rs2243115) have no influence on cancer susceptibility in both hospital-based and population-based controls subgroups (all *P* \> 0.05).

![Forest plot of OR with 95%CI for the IL-12 polymorphisms with cancer risk under dominant model (**A**) rs568408; (**B**) rs2243115). CI: confidence interval, OR: odds ratio.](oncotarget-08-29795-g002){#F2}

Quantitative synthesis of rs3212227 polymorphism {#s2_3}
------------------------------------------------

We gained 9950 patients and 11180 control subjects from 30 studies of rs3212227 polymorphism. IL-12B rs3212227 was proved to enhance overall cancer risk (C vs. A: OR = 1.15, 95%CI: 1.05-1.25; CC vs. AA: OR = 1.32, 95%CI: 1.11-1.56; AC vs. AA: OR= 1.21, 95%CI: 1.08-1.35, *P* = 0.001; AC+CC vs. AA: OR = 1.24, 95%CI: 1.10-1.40, *P* \< 0.001; CC vs. AC+AA: OR = 1.17, 95%CI: 1.04-1.31). The similar results were obtained after excluding studies with HWE disequilibrium (C vs. A: OR = 1.14, 95%CI: 1.05-1.25; CC vs. AA: OR = 1.33, 95%CI: 1.12-1.58; AC vs. AA: OR = 1.19, 95%CI: 1.06-1.34; AC+CC vs. AA: OR = 1.23, 95%CI: 1.09-1.38; CC vs. AC+AA: OR = 1.18, 95%CI: 1.05-1.32).

When stratification analysis performed by ethnicity (Figure [3](#F3){ref-type="fig"}), rs3212227 polymorphism exhibited to increase overall cancer risk among Asians (AC+CC vs. AA: OR = 1.29, 95%CI: 1.15-1.46; CC vs. AC+AA: OR = 1.17, 95%CI: 1.06-1.30; CC vs. AA: OR = 1.38, 95%CI: 1.17-1.62; AC vs. AA: OR = 1.25, 95%CI: 1.11-1.40; C vs. A: OR = 1.18, 95%CI: 1.09-1.28). In subgroup analysis by cancer type (Figure [4](#F4){ref-type="fig"}), rs3212227 was found to increase the risk of hepatocellular carcinoma (AC+CC vs. AA: OR = 1.24, 95%CI: 1.09-1.40; CC vs. AC+AA: OR = 1.17, 95%CI: 1.00-1.37; CC vs. AA: OR = 1.30, 95%CI: 1.07-1.59; AC vs. AA: OR = 1.17, 95%CI: 1.02-1.35; C vs. A: OR = 1.14, 95%CI: 1.04-1.25) and nasopharyngeal carcinoma (AC+CC vs. AA: OR = 2.03, 95%CI: 1.57-2.63; CC vs. AC+AA: OR = 1.66, 95%CI: 1.23-2.25; CC vs. AA: OR = 2.49, 95%CI: 1.75-3.54; AC vs. AA: OR = 1.88, 95%CI: 1.43-2.47; C vs. A: OR = 1.60, 95%CI: 1.34-1.90). When conducted a stratified analysis by the source of controls, rs3212227 polymorphism displayed an increased cancer risk among population-based studies and hospital-based studies in different comparison models. The detail results were listed in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

![Stratified analysis by ethnicity for the association between IL-12 rs3212227 polymorphism and cancer risk under dominant model (CC + AC vs. AA) according to the HWE\
CI: confidence interval, OR: odds ratio, HWE: Hardy--Weinberg equilibrium.](oncotarget-08-29795-g003){#F3}

![Stratified analysis by cancer type for the association between IL-12B rs3212227 polymorphism and cancer risk under dominant model (CC + AC vs. AA) according to the HWE\
CI: confidence interval, OR: odds ratio. HCC: hepatocellular carcinoma; GC: gastric cancer; CRC: colorectal cancer; BC: breast cancer; PC: prostate cancer; OSC: osteosarcoma; EC: esophageal cancer; BLC: bladder cancer; BT: brain tumor; CC: cervical cancer; OC: ovarian carcinoma; NPC: nasopharyngeal cancer; GC: gastric cancer; LC: lung cancer; NHL: non-Hodgkin lymphoma; CMM: cutaneous malignant melanoma, HWE: Hardy--Weinberg equilibrium.](oncotarget-08-29795-g004){#F4}

Heterogeneity and sensitivity analysis {#s2_4}
--------------------------------------

For the overall study, statistically significant heterogeneity existed in rs568408 polymorphism (AA+GA vs. GG, *P* \< 0.0001, I^2^ = 82%; AA vs. GA+GG, *P* = 0.001, I^2^ = 68%; AA vs. GG, *P* = 0.009, I^2^ = 59%; GA vs. GG, *P* \< 0.0001, I^2^ = 88%; A vs. G, *P* \< 0.0001, I^2^ = 70%) and rs3212227 polymorphism (AC+CC vs. AA, *P* \< 0.0001, I^2^ = 72%; CC vs. AA, *P* \< 0.0001, I^2^ = 65%; AC vs. AA, *P* \< 0.0001, I^2^ = 66%; C vs. A, *P* \< 0.0001, I^2^ = 74%). Therefore, we conducted further subgroup analyses by cancer type, ethnicity and source of control ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The sequential leave-one-out sensitivity analysis was adopted to evaluate each individual study\'s influence on the overall risk estimates. However, the results proved there was no single study could skew the pooled ORs significantly, indicating the credibility and reliability of this meta-analysis (shown in Figure [5](#F5){ref-type="fig"}).

![Sensitivity analysis of the associations between IL12 polymorphisms and cancer risk (**A**) rs568408; (**B**) rs2243115; (**C**) rs3212227).](oncotarget-08-29795-g005){#F5}

Publication bias {#s2_5}
----------------

Publication bias of the eligible studies of these IL-12 polymorphisms was accessed by funnel plot and Egger\'s test. The symmetrical shapes of the funnel plots (Figure [6](#F6){ref-type="fig"}) and further statistical evidence provided by Egger\'s test (Table [3](#T3){ref-type="table"}) showed the absence of publication bias (*P* \> 0.05).

![Funnel plots of publication bias (**A**) rs568408; (**B**) rs2243115; (**C**) rs3212227).](oncotarget-08-29795-g006){#F6}

###### Egger\'s test for publication bias test of IL-12 polymorphisms

  Egger's test           Coefficient   SE          t       P \> \|t\|   95%CI
  -------------- ------- ------------- ----------- ------- ------------ ---------------------
  rs568408       slope   0.552139      0.228511    2.42    0.046        0.0117964--1.092481
                 bias    −3.03665      1.803099    −1.68   0.136        −7.300299--1.227003
  rs2243115      slope   −0.20484      0.284498    −0.72   0.495        −0.877572--0.467887
                 bias    1.303655      1.599617    0.81    0.442        −2.837692--6.454866
  rs3212227      slope   −0.0187827    0.1555829   −0.12   0.905        −3380125--0.300447
                 bias    1.225427      0.9578139   1.28    0.212        −7398447--3.190699

SE: standard error; 95%CI: 95% confidence interval.

DISCUSSION {#s3}
==========

Attracted to the effects of IL-12 polymorphisms in the onset risk of cancer, many researchers performed numerous molecular epidemiological studies to explore the connection. Regrettably, they were failed to achieve a coincident conclusion. Existing epidemiological studies showed a higher interest on the SNP of rs3212227 in IL-12B gene, but put less focus on the rs568408 and rs2243115 SNPs of IL-12A genes. Only one meta-analysis (including eighteen studies) focused on IL-12A polymorphisms and suggested that both rs568408 and rs2243115 polymorphisms of IL-12A did not connect with cancer susceptibility \[[@R29]\]. In our meta-analysis, we observed that rs568408 polymorphism increased cervical cancer risk and overall cancer risk among Caucasians, while rs2243115 polymorphism may be a high risk factor of brain tumor. And, the mutant C allele of rs3212227 polymorphism was proved to contribute to overall cancer\'s development, especially for hepatocellular carcinoma, nasopharyngeal cancer and among Asians.

What we found in this meta-analysis is contrary to the previous meta-analyses \[[@R29], [@R30]\], our study proved no association between cervical cancer and rs3212227 polymorphism, while rs568408 and rs2243115 polymorphisms were associated with cervical cancer and brain tumor respectively. Compared to the previous meta-analyses, this study included more eligible studies, conducted more detailed subgroup analyses, and also performed stringent quality control during data statistics. Thus, our results are more comprehensive and persuasive. In the past years, we considered only IL-12B polymorphism played an important role in cancer development and looked down on the function of IL-12A. This meta-analysis indicated that we should perform more comprehensive investigation both on the respective function and interaction of IL-12A and IL-12B.

As is depicted in introduction, IL-12 is a multiple effective cytokine that links the innate (NK cells) and acquirs (cytotoxic T lymphocytes) immune response \[[@R7]\]. Structurally, IL-12 is a heterodimer consisted of a 35 kD α-chain (p35 subunit) and a 40 kD β-chain (p40 subunit), the latter was shared with IL-23, another important member from IL-12 family. P35 and p40 are encoded by IL-12 A and IL-12 B gene, respectively. And, IL-12 p40 is produced in excess over the IL-12 and IL-23 heterodimers in average level \[[@R31]\]. We guess the amount of activated IL-12B gene was much more than activated IL-12A gene, thus we observed more mutation frequency in IL-12B rs3212227. In fact, both IL-12A and IL-12B gene have played a role in the development of cancer. Therefore, we speculated IL-12 polymorphisms may alter the IL-12 gene expression, decrease functional IL-12 protein synthesis, which ultimately brought about immune system dysfunction and lead to the development of malignant tumors. The clinical trials of IL-12 were rather disappointing, because systemic administration in cancer treatment was observed defined anti-tumor efficacy and severe toxic effects. Thus, it was now vigorously promoted to develop the gene therapy vectors which can express activated IL-12 locally in tumors. New avenues for IL-12 in cancer have been opened with technical advances in recent years, which are currently under research \[[@R32]\]. Our meta-analysis provided a direction to the further vivo and *in vitro* experiments.

Some possible limitations in this study need to be attended. Firstly, some potential source of heterogeneity, such as sex and environmental exposures, may have influence on the final results of the present study. Secondly, environmental factors were failed to evaluate, because lack of relevant data, such as family history, age, lifestyle, which might alter the real relation of IL-12 polymorphisms and the cancer risk. Thirdly, studies written in a third language were excluded (not in English or Chinese), thus, selection bias is inevitable. Fourthly, although we pooled all eligible publications together in our study, the sample size for some types of cancer were still small. For instance, there was only one or two literature available for cervical cancer. Thus, we should be cautious to explain our results. Finally, publication bias may exist in our meta-analysis because we could not gain the unpublished data.

In conclusion, this meta-analysis draws a reliable conclusion that these IL-12 polymorphisms (rs568408, rs2243115 and rs3212227) might be high risk factors for cancer, which indicated IL-12 may serve as a promising marker for cancer screening. Further well-designed multi-center studies with larger sample sizes (especially for rs568408 and rs2243115 polymorphisms of IL-12A) and detailed gene-environmental interactions are warranted to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

We followed the PRISMA statement to guide the process of this meta-analysis \[[@R33]\] {#s4_1}
--------------------------------------------------------------------------------------

### Search strategy {#s4_1_1}

We obtained eligible studies prior to October 2016 from the PubMed, web of knowledge, Embase, WanFang, VIP and CNKI databases, using the terms: "cancer or carcinoma or tumor or neoplasm" and "polymorphism or variant or variation" and "interleukin-12 or IL-12". In addition, we manually screened the references in the relevant reviews to ensure all relevant studies were not missed. Studies elected in this meta-analysis met the criteria as follows: (1) case-control studies evaluated the association of IL-12A rs568408, IL-12A rs2243115, or IL-12B rs3212227 polymorphisms with various cancer risks; (2) genotype distributions were sufficient for both cases and controls for data extraction; (3) published in English or Chinese. And we adopted following exclusion criteria: (1) repeat of previous studies, reviews, or abstracts; (2) not case-control design; (3) absence of detailed genotyping data; (4) duplication of previous data. If the overlap of data appeared in different publications, the paper included more samples were chosen.

Data extraction and quality assessment {#s4_2}
--------------------------------------

Two investigators independently elected for following information from the all eligible studies: first author, publication year, cancer type, country, ethnicity, source of controls, genotyping platform, total number of cases and controls, genetic distribution among cases and controls, and Hardy--Weinberg equilibrium (HWE) *P value* of controls. The subgroup analyses were performed according to cancer type, ethnicity (Asians, Caucasians), and source of controls. All patients in case group were confirmed by histology or pathology. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the eligible studies \[[@R34]\], The total scores ranged from 0 to 10, with higher scores indicating better quality. Score of 0--5, 6-9 was considered as indicative of a low-, high-quality study, respectively. To resolve all disagreements of two investigators, a discussion with a senior investigator was conducted until a consensus was reached.

Statistical analysis {#s4_3}
--------------------

To evaluate the cancer risk associated IL-12 polymorphisms (rs568408, rs2243115, rs3212227), we calculated ORs and 95% CI based on the genotypes in cases and controls. Five different genetic models were evaluated: (i) BB+ AB vs. AA (dominant model), (ii) BB vs. AA (homozygote model), (iii) AB vs. AA (heterozygote model), (iv) BB vs. AA+ AB (recessive model), (v) B vs. A (allele comparison). "A" represents the wild allele, while "B" represents the mutation allele. Heterogeneity among the studies was checked by Chi-square-based Q statistic and I^2^ test, and it was regarded as homogeneous if *P* \> 0.10 in Chi-square-based Q statistic. When the effects were assumed to be homogeneous, we used the fixed-effects model to assess the pooled OR. Otherwise, the random-effects model was chosen. Furthermore, source of heterogeneity among studies was explored by subgroup analyses base on cancer type, ethnicity and source of control. We adopted Begg\'s and Egger\'s test to evaluate the possible sources of bias. Sensitivity analysis was chiefly performed by orderly removing individual study and rechecked the pooled ORs to assess the stability of the final results. All statistical analyses in this study were performed by software STATA (Version 14.0; Stata Corp, College Station, TX). A statistical significance was considered if *P* \< 0.05 and all the statistics were two-sided.
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